Sansure Biotech Inc. (SHA:688289)
China
· Delayed Price · Currency is CNY 18.41
+0.07 (0.38%)
Mar 9, 2026, 3:00 PM CST
Sansure Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Net Income | - | 226.27 | 348.17 | 1,937 | 2,243 | Upgrade
|
| Depreciation & Amortization | - | 149.65 | 116.9 | 89.07 | 53.94 | Upgrade
|
| Other Amortization | - | 20.92 | 19.87 | 8.35 | 5.01 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 2.36 | 0.25 | 0.31 | -2.83 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | -5.31 | -54.88 | 21.69 | 2.42 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | 33.7 | -253.74 | -79.24 | -81.01 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 13.71 | 4.98 | 45.96 | 18.49 | Upgrade
|
| Other Operating Activities | - | -25.6 | -13.92 | 271.83 | 36.64 | Upgrade
|
| Change in Accounts Receivable | - | 153.01 | 376.54 | -496.51 | -304.14 | Upgrade
|
| Change in Inventory | - | 36.46 | -78.3 | -282.1 | -93.03 | Upgrade
|
| Change in Accounts Payable | - | -305.37 | -421.3 | 1,022 | 3.12 | Upgrade
|
| Change in Other Net Operating Assets | - | -27.17 | -42.16 | 60.85 | 3.84 | Upgrade
|
| Operating Cash Flow | - | 274.45 | 43.54 | 2,559 | 1,877 | Upgrade
|
| Operating Cash Flow Growth | - | 530.34% | -98.30% | 36.33% | -28.96% | Upgrade
|
| Capital Expenditures | - | -421.1 | -391.35 | -558.83 | -372.86 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.25 | 0.72 | 0.01 | 15.94 | Upgrade
|
| Cash Acquisitions | - | -1.07 | -113 | -11.59 | - | Upgrade
|
| Divestitures | - | -58.28 | - | - | - | Upgrade
|
| Sale (Purchase) of Real Estate | - | - | - | - | 1.77 | Upgrade
|
| Investment in Securities | - | 363.67 | 1,791 | -642.46 | -834.95 | Upgrade
|
| Other Investing Activities | - | 14.61 | 110.03 | 46.13 | 77.88 | Upgrade
|
| Investing Cash Flow | - | -101.92 | 1,398 | -1,167 | -1,112 | Upgrade
|
| Long-Term Debt Issued | - | 403.13 | 18 | - | - | Upgrade
|
| Total Debt Issued | - | 403.13 | 18 | - | - | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -55 | Upgrade
|
| Long-Term Debt Repaid | - | -31.29 | -23.91 | -17.18 | -6.27 | Upgrade
|
| Total Debt Repaid | - | -31.29 | -23.91 | -17.18 | -61.27 | Upgrade
|
| Net Debt Issued (Repaid) | - | 371.84 | -5.91 | -17.18 | -61.27 | Upgrade
|
| Issuance of Common Stock | - | 21.45 | - | - | - | Upgrade
|
| Repurchase of Common Stock | - | - | -122.73 | -257.41 | -200.01 | Upgrade
|
| Common Dividends Paid | - | -268.4 | -400.46 | -656.93 | -439.89 | Upgrade
|
| Other Financing Activities | - | 7.6 | 160 | 15.57 | 12.58 | Upgrade
|
| Financing Cash Flow | - | 132.49 | -369.11 | -915.95 | -688.59 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | -0 | 0.34 | -10.01 | -34.25 | Upgrade
|
| Net Cash Flow | - | 305.01 | 1,073 | 466.24 | 42.01 | Upgrade
|
| Free Cash Flow | - | -146.66 | -347.81 | 2,000 | 1,504 | Upgrade
|
| Free Cash Flow Growth | - | - | - | 32.97% | -40.63% | Upgrade
|
| Free Cash Flow Margin | - | -10.06% | -34.53% | 31.01% | 33.32% | Upgrade
|
| Free Cash Flow Per Share | - | -0.25 | -0.59 | 3.42 | 2.56 | Upgrade
|
| Cash Interest Paid | - | - | - | - | 0.32 | Upgrade
|
| Cash Income Tax Paid | - | 112.34 | 121.48 | 493.44 | 466.25 | Upgrade
|
| Levered Free Cash Flow | - | -206.02 | -227.68 | 1,293 | 898.55 | Upgrade
|
| Unlevered Free Cash Flow | - | -194.52 | -226.17 | 1,295 | 899.06 | Upgrade
|
| Change in Working Capital | - | -141.26 | -124.08 | 264.17 | -398.29 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.